Compare CENTA & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENTA | VERA |
|---|---|---|
| Founded | 1955 | 2016 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | CENTA | VERA |
|---|---|---|
| Price | $36.98 | $33.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $36.75 | ★ $81.30 |
| AVG Volume (30 Days) | 249.6K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | $472.48 |
| P/E Ratio | $13.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.97 | $19.07 |
| 52 Week High | $37.71 | $56.05 |
| Indicator | CENTA | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 70.49 | 46.85 |
| Support Level | $33.34 | $31.70 |
| Resistance Level | $37.71 | $42.77 |
| Average True Range (ATR) | 0.83 | 2.29 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 93.88 | 45.22 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.